Biography
David is a scientist at heart and a respected leader in cell therapy, with a singular focus on advancing the next breakthrough: allogeneic CAR T products. Before joining Allogene, he was Executive Vice President of RD and Chief Medical Officer at Kite, a Gilead Company. He has an industry-leading track record in oncology drug development, including Yescarta (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma, Blincyto (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia, IMLYGIC (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma, among others. From 2002 to 2014, he held senior leadership roles at Amgen, and earlier, served on the faculty at the David Geffen School of Medicine at the University of California, Los Angeles.